BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 21514245)

  • 1. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.
    Blasco RB; Francoz S; Santamaría D; Cañamero M; Dubus P; Charron J; Baccarini M; Barbacid M
    Cancer Cell; 2011 May; 19(5):652-63. PubMed ID: 21514245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-Raf is required for the initiation of lung cancer by K-Ras(G12D).
    Karreth FA; Frese KK; DeNicola GM; Baccarini M; Tuveson DA
    Cancer Discov; 2011 Jul; 1(2):128-36. PubMed ID: 22043453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase A phosphorylation.
    Li Y; Takahashi M; Stork PJS
    J Biol Chem; 2013 Sep; 288(38):27646-27657. PubMed ID: 23893412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
    Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
    Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
    Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of B-RAF in oncogenic C-RAF-expressing alveolar epithelial type II cells reduces MAPK signal intensity and lung tumor growth.
    Zanucco E; El-Nikhely N; Götz R; Weidmann K; Pfeiffer V; Savai R; Seeger W; Ullrich A; Rapp UR
    J Biol Chem; 2014 Sep; 289(39):26804-26816. PubMed ID: 25096573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis.
    Kern F; Doma E; Rupp C; Niault T; Baccarini M
    Oncogene; 2013 May; 32(19):2483-92. PubMed ID: 22733131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.
    Ko JC; Syu JJ; Chen JC; Wang TJ; Chang PY; Chen CY; Jian YT; Jian YJ; Lin YW
    Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):383-91. PubMed ID: 26046675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway.
    Lin M; Bi H; Yan Y; Huang W; Zhang G; Zhang G; Tang S; Liu Y; Zhang L; Ma J; Zhang J
    Oncotarget; 2017 Apr; 8(14):23436-23447. PubMed ID: 28423582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease in K-ras p21 and increase in Raf1 and activated Erk 1 and 2 in murine lung tumors initiated by N-nitrosodimethylamine and promoted by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
    Ramakrishna G; Perella C; Birely L; Diwan BA; Fornwald LW; Anderson LM
    Toxicol Appl Pharmacol; 2002 Feb; 179(1):21-34. PubMed ID: 11884234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W
    Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
    Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
    Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
    Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
    Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression.
    Kim DI; Lee SJ; Lee SB; Park K; Kim WJ; Moon SK
    Carcinogenesis; 2008 Sep; 29(9):1701-9. PubMed ID: 18296682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
    Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumour suppressor DiRas3 interacts with C-RAF and downregulates MEK activity to restrict cell migration.
    Klingauf M; Beck M; Berge U; Turgay Y; Heinzer S; Horvath P; Kroschewski R
    Biol Cell; 2013 Feb; 105(2):91-107. PubMed ID: 23157514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade.
    Kim PN; Jonasch E; Mosterman BC; Mier JW; Janssen RA
    Cell Growth Differ; 2001 Nov; 12(11):543-50. PubMed ID: 11714635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells.
    Ravi RK; Thiagalingam A; Weber E; McMahon M; Nelkin BD; Mabry M
    Am J Respir Cell Mol Biol; 1999 Apr; 20(4):543-9. PubMed ID: 10100985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation.
    Lahlou H; Saint-Laurent N; Estève JP; Eychène A; Pradayrol L; Pyronnet S; Susini C
    J Biol Chem; 2003 Oct; 278(41):39356-71. PubMed ID: 12878607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.